DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
AC Camargo Cancer Center
Universidad Nacional Autonoma de Mexico
University Medical Center Groningen
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)